ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

EFFECTIVENESS OF GLIMEPIRIDE ON THE PATIENTS SUFFERING FROM TYPE 2 DIABETES

Dr. Zain Ghani, Dr Muhammad Ammar Maqsood, Dr. Tahura Rasul.

Objective: This case work aimed to assess the effectiveness of the glimepiride going beyond four milligram in our routine practice, since the reaction of this drug is reproducibly dependent on dose and maximum dose of the glimepiride can be up to eight milligrams. Methodology: This study was a prospective research work in which we selected one hundred and thirteen participants (Fifty-six males & fifty-seven females) from the outpatient department of the Sir Ganga Ram Hospital, Lahore. This case work started from 1 November 2017 and last participant got enrollment on 31 August 2018. We gave 6 to 8 milligram glimepirides to the patients with HbA1c greater than 8.0% on the highest dose of other OHA (oral hypoglycemic agents) & we followed up the treatment. We rechecked the HbA1c after 3 to 6 months and this was the finish point for the patients in this research work. Results: The average baseline HbA1c of all the patients was about 10.170%. We followed the patients and HbA1c carried out after a mean duration of five months. Level of HbA1c of the patients continuing on six milligram glimepirides (n: 103) was 8.730% whereas those patients on eight milligrams (n: 10) was 8.260%. Adjusted average disparity of HbA1c from baseline to the 2nd specimen for six milligrams was -1.44% & for eight milligrams was -1.910% which was statistically important. So, the reduction of the percentage in the average HbA1c for six milligrams was 14.20% & for eight milligrams was 18.80% correspondingly in the subjects of this research work. Conclusion: The decrease of the average HbA1c prior and after therapy in both the six & eight milligram groups was statistically important over the duration of this research study. Key Word: Glimepiride, milligram, Type-2 diabetes, research study, methodology, dependent, reaction, average.

FULL TEXT